C
25.50
4.46 (21.20%)
| Previous Close | 21.04 |
| Open | 21.52 |
| Volume | 276,819 |
| Avg. Volume (3M) | 141,847 |
| Market Cap | 330,729,888 |
| Price / Earnings (Forward) | 5.75 |
| Price / Sales | 99.60 |
| Price / Book | 1.34 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Operating Margin (TTM) | -7,154.43% |
| Diluted EPS (TTM) | -26.82 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 2.19% |
| Current Ratio (MRQ) | 4.25 |
| Operating Cash Flow (TTM) | -176.53 M |
| Levered Free Cash Flow (TTM) | -67.09 M |
| Return on Assets (TTM) | -40.46% |
| Return on Equity (TTM) | -219.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Cidara Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak® platform targeting oncologic, viral and autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.38% |
| % Held by Institutions | 69.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vr Adviser, Llc | 31 Mar 2025 | 1,051,518 |
| Tcg Crossover Management, Llc | 31 Mar 2025 | 1,005,901 |
| Bain Capital Life Sciences Investors, Llc | 31 Mar 2025 | 703,080 |
| Acuta Capital Partners, Llc | 31 Mar 2025 | 125,708 |
| Aberdeen Group Plc | 31 Mar 2025 | 120,879 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Guggenheim, 96.08%) | Buy |
| Median | 46.00 (80.39%) | |
| Low | 35.00 (Needham, 37.26%) | Buy |
| 35.00 (HC Wainwright & Co., 37.26%) | Buy | |
| Average | 42.60 (67.06%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 21.32 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 16 May 2025 | 50.00 (96.08%) | Buy | 25.50 |
| 09 May 2025 | 35.00 (37.25%) | Buy | 18.63 | |
| JMP Securities | 09 May 2025 | 47.00 (84.31%) | Buy | 18.63 |
| 29 Apr 2025 | 46.00 (80.39%) | Buy | 21.12 | |
| Needham | 10 Apr 2025 | 35.00 (37.25%) | Buy | 17.09 |
| 07 Mar 2025 | 35.00 (37.25%) | Buy | 23.66 | |
| Citizens Capital Markets | 12 Mar 2025 | 46.00 (80.39%) | Buy | 23.00 |
| HC Wainwright & Co. | 10 Mar 2025 | 35.00 (37.25%) | Buy | 22.39 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |